Knight Therapeutics Inc (TSX:GUD)

C$ 5.43 0.02 (0.37%) Market Cap: 550.47 Mil Enterprise Value: 428.31 Mil PE Ratio: 0 PB Ratio: 0.72 GF Score: 87/100

Q4 2023 Knight Therapeutics Inc Earnings Call Transcript
Mar 21, 2024

C$5.23 (-2.97%)

Earnings
Q3 2023 Knight Therapeutics Inc Earnings Call Transcript
Nov 09, 2023

C$4.99 (+4.39%)

Earnings
Q2 2023 Knight Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

C$4.84 (+0.21%)

Earnings
Q1 2023 Knight Therapeutics Inc Earnings Call Transcript
May 11, 2023

C$4.81 (+2.12%)

Earnings
Knight Therapeutics Inc Annual Shareholders Meeting Transcript
May 10, 2023
Q4 2022 Knight Therapeutics Inc Earnings Call Transcript
Mar 23, 2023

C$4.84 (-1.22%)

Earnings
Q3 2022 Knight Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

C$5.31 (-1.67%)

Earnings
Q2 2022 Knight Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

C$5.97 (+7.37%)

Earnings
Q1 2022 Knight Therapeutics Inc Earnings Call Transcript
May 12, 2022

C$5.19 (-0.57%)

Earnings
Knight Therapeutics Inc Annual Shareholders Meeting Transcript
May 11, 2022
Q4 2021 Knight Therapeutics Inc Earnings Call Transcript
Mar 24, 2022

C$5.22 (-6.12%)

Earnings
Q3 2021 Knight Therapeutics Inc Earnings Call Transcript
Nov 11, 2021

C$5.29 (+0.76%)

Earnings
Q2 2021 Knight Therapeutics Inc Earnings Call Transcript
Aug 13, 2021

C$5.6 (+8.95%)

Earnings
Q1 2021 Knight Therapeutics Inc Earnings Call Transcript
May 14, 2021

C$5.35 (+1.90%)

Earnings
Knight Therapeutics Inc Host A Conference Call To Discuss The Exelon Acquisition Transcript
Apr 23, 2021
Q4 2020 Knight Therapeutics Inc Earnings Call Transcript
Mar 25, 2021

C$5.23 (+4.81%)

Earnings
Q3 2020 Knight Therapeutics Inc Earnings Call Transcript
Nov 13, 2020

C$5.39 (-0.37%)

Earnings
Q2 2020 Knight Therapeutics Inc Earnings Call Transcript
Aug 13, 2020

C$6.75 (+0.45%)

Earnings
Q1 2020 Knight Therapeutics Inc Earnings Call Transcript
Jun 26, 2020

C$6.82 (-6.19%)

Earnings
Knight Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Q4 2019 Knight Therapeutics Inc Earnings Call Transcript
Mar 30, 2020

C$6.13 (+2.34%)

Earnings
Q3 2019 Knight Therapeutics Inc Earnings Call Transcript
Nov 12, 2019

C$8.08 (-1.70%)

Earnings
Knight Therapeutics Inc M&A Call Transcript
Oct 21, 2019
Q2 2019 Knight Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

C$7.44 (+0.81%)

Earnings
Q1 2019 Knight Therapeutics Inc Earnings Call Transcript
May 09, 2019

C$7.47 (-0.40%)

Earnings
Q4 2018 Knight Therapeutics Inc Earnings Call Transcript
Mar 14, 2019

C$7.55 (+0.27%)

Earnings

Knight Therapeutics Inc Annual Shareholders Meeting Transcript

May 11, 2022 / 01:00PM GMT

Release Date Price: C$5.22 (-1.69%)

Transcript

Operator

Hello, you are joining Knight Therapeutics Annual General Meeting. I would now like to turn the call over to Jonathan Goodman, Chairman of the meeting. You may begin.

Jonathan Ross Goodman

Knight Therapeutics Inc. - Executive Chairman

Good morning, ladies and gentlemen. Welcome to Knight Therapeutics' Annual Meeting of Shareholders. Once again, this year, we have chosen to hold the meeting via live audio webcast. My name is Jonathan Goodman, Executive Chairman of Knight Therapeutics, and I will chair today's meeting.

Also with me on the call is Samira Sakhia, our President and CEO; and Bryan Kujawski, our External Counsel. Samira will act as secretary of today's meeting. Steve Gilbert and Claire Girard of Computershare Investor Services will be acting as scrutineers for this meeting.

Our agenda today is straightforward. First, we will conduct the formal part of our meeting. Following the formal part of the meeting, Samira will make a few remarks. Finally, we will do our best to answer any questions you may have. Questions, objections,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.